The least squares ( LS ) mean change ( 95 % confidence interval ) from baseline in HbA1c at week 24 was -0.028 % ( -0.192 to 0.137 ) in the placebo group , compared with -0.797 % ( -0.960 to -0.634 ) in the tofogliflozin 10 mg group , -1.017 % ( -1.178 to -0.856 ) in the tofogliflozin 20 mg group , and -0.870 % ( -1.031 to -0.709 ) in the tofogliflozin 40 mg group ( p < 0.0001 for the LS mean differences in all tofogliflozin groups vs placebo ) .